Citi analyst Geof Meacham raised the firm’s price target on Avidity Biosciences (RNA) to $75 from $70 and keeps a Buy rating on the shares. The company announced positive regulatory alignment and topline clinical data supporting the accelerated approval pathway of del-brax in Facioscapulohumeral muscular dystrophy, the analyst tells investors in a research note. The firm says that along with 12-month functional data showing a clinically meaningful response, it is encouraged by the potential for an application filing in the second half of 2026. Citi increased its probability of sucess for del-brax to 80% from 70% and remains buyers on Avidity shares on weakness.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences price target raised to $59 from $57 at Barclays
- Avidity data strengthens accelerated approval case, says H.C. Wainwright
- Avidity Biosciences price target raised to $65 from $60 at Leerink
- Avidity Biosciences Receives Buy Rating Due to Promising FSHD Program Developments and Accelerated FDA Approval Pathway
- Avidity Biosciences price target raised to $54 from $48 at BofA